- Home
- WEA vs MCRB Comparison
WEA vs MCRB Comparison
Compare WEA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | MCRB |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 139.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WEA | MCRB |
|---|---|---|
| Price | $10.98 | $8.74 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 32.2K | ★ 93.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 2.40 |
| Revenue | N/A | ★ $126,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.43 |
| Revenue Growth | N/A | ★ 1672.24 |
| 52 Week Low | $10.16 | $0.36 |
| 52 Week High | $11.44 | $29.98 |
Technical Indicators
Market Signals| Indicator | WEA | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 26.09 |
| Support Level | $10.86 | $7.12 |
| Resistance Level | $11.04 | $8.49 |
| Average True Range (ATR) | 0.10 | 1.13 |
| MACD | -0.02 | -0.42 |
| Stochastic Oscillator | 12.77 | 5.42 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.